FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Brennan Peter F 		2. Issuer Name and Ticker or Trading Symbol

CALMARE THERAPEUTICS Inc [ CTTC ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

1375 KINGS HIGHWAY EAST 		3. Date of Earliest Transaction (MM/DD/YYYY)

2/12/2018
(Street)

FAIRFIELD, CT 06824
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   2/12/2018     M    4594117   A   (1) (2) (3) (4) (5) 13850181   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant   $0.6   2/12/2018     C      123530         (1)   (1) Common Stock   123530   $0.6   123530   D    
Warrant   $0.6   2/12/2018     C      411765         (2)   (2) Common Stock   411765   $0.6   535295   D    
Warrant   $0.13   2/12/2018     C      764706         (3)   (3) Common Stock   764706   $0.13   1300001   D    
Warrant   $0.13   2/12/2018     C      1882362         (4)   (4) Common Stock   1882362   $0.13   3182353   D    
Warrant   $0.125   2/12/2018     C      1411765         (5)   (5) Common Stock   1411765   $0.125   4594117   D    

Explanation of Responses:
(1)  The Reporting Person received a warrant to purchase 123,530 shares of Common Stock on 02/23/2017 inconnection with a Note Purchase Agreement executed on that date. The exercise price was $0.60 per share. The warrant was exercisable immediately and expired in one year-02/23/2018.
(2)  The Reporting Person received a warrant to purchase 411,765 shares of Common Stock on 05/16/2017 in connection with a Note Purchase Agreement executed on that date. The exercise price was $0.60 per share. The warrant was exercisable immediately and expired in one year-05/16/2018.
(3)  The Reporting Person received a warrant to purchase 764,706 shares of Common Stock on 07/24/2017 in connection with a Note Purchase Agreement executed on that date. The exercise price was $0.13 per share. The warrant was exercisable immediately and expired in one year - 07/24/2018.
(4)  The Reporting Person received a warrant to purchase 1,882,352 shares of Common Stock on 12/29/2017 in connection with a Note Purchase Agreement executed on that date. The exercise price was $0.13 per share. The warrant was exercisable immediately and expired in one year-12/29/2018.
(5)  The Reporting Person received a warrant to purchase 1,411,765 shares of Common Stock on 02/01/2018 in connection with a Note Purchase Agreement executed on that date. The exercise price was $0.125 per share. The warrant was exercisable immediately and expired in one year- 02/01/2019.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Brennan Peter F
1375 KINGS HIGHWAY EAST
FAIRFIELD, CT 06824 		X



Signatures
/s/ Peter Brennan 3/6/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Calmare Therapeutics (CE) (USOTC:CTTC)
Historical Stock Chart
From Jul 2024 to Aug 2024 Click Here for more Calmare Therapeutics (CE) Charts.
Calmare Therapeutics (CE) (USOTC:CTTC)
Historical Stock Chart
From Aug 2023 to Aug 2024 Click Here for more Calmare Therapeutics (CE) Charts.